Bare Financial Services’s Recursion Pharmaceuticals RXRX Stock Holding History

Bare Financial Services’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$677	Buy	+164	New	+$556	﹤0.01%	1631

Other funds holding RXRX

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $296B AUM 23.14% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Bare Financial Services's RXRX Position: Q3 2026 in Review

Bare Financial Services opened a new position in Recursion Pharmaceuticals (RXRX) in Q3 2026: 164 shares worth $677. The stake represents ﹤0.01% of the portfolio and ranks #1631 among its holdings.

215 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

Bare Financial Services held 164 shares of Recursion Pharmaceuticals worth $677 as of Q3 2026.
Recursion Pharmaceuticals was a new Bare Financial Services position in Q3 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Bare Financial Services's portfolio in Q3 2026, its #1631 holding.
215 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Bare Financial Services's 13F filing for Q3 2026, filed 4 Nov 2026.